Qualcomm secures German injunction; Chinese patent linkage plans seem doomed; US patent litigation filings set to drop below 4,000 for 2018; and much more
In the week before the Christmas break the IAM team was busy covering stories across three continents – including another major win for Qualcomm in its on-going patent tussle with Apple and news of another big drop in US litigation filings. Here’s what you missed …
MONDAY 17th December
Proposals to introduce a US-style Orange Book system seem to have been shelved in China, showing pharma innovators’ limited influence in the country. Read more here
Study claims that doubling the hours allotted for examination of patent applications at the USPTO would reduce burden on rights owners in courts and at the PTAB, saving them $900 million a year. Read more here
TUESDAY 18th December
As Huawei and Samsung slug it out in their SEP licensing dispute, the Korean company's chipmaking division fears crucial trade secrets have already made their way to Shenzhen. Read more here
The volume of new US patent litigation cases is forecast to fall to under 4,000 for the first time since 2011 - and to well below levels for trademark and copyright suits. Read more here
WEDNESDAY 19th December
With the festive season now upon us, those looking for gift ideas can delve into the wonderful world of patents for inspiration. Read more here
THURSDAY 20th December
Qualcomm secures German iPhone injunction against Apple from District Court of Munich and it could be spur to settlement talks. Read more here
Apple says it is in full compliance with Qualcomm injunctions issued 10 days ago in Fuzhou, but has come in in for sharp criticism in the Chinese press. Read more here
MIT and Harvard lead the world’s research institutions in patent quality, but look out for the rise of centres based in Asia. Read more here
FRIDAY 21st December
A summary of the major IP news from the biotechnology, pharmaceutical and medical technology sectors in November and the first-half of December. Read more here
Everything you need to know about China’s new preliminary injunction rules, which were published in late November. Read more here
Lame duck Congress session attempt at pharma IPR reform looks likely to fail given recent changes at the PTAB and growing public concern over drugs pricing in the US. Read more here